Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 18 | 2025 | 334 | 4.860 |
Why?
|
| Brain Neoplasms | 23 | 2025 | 1236 | 4.330 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2025 | 1117 | 1.570 |
Why?
|
| Glioma | 4 | 2022 | 496 | 1.520 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2025 | 74 | 1.460 |
Why?
|
| Astrocytoma | 2 | 2022 | 103 | 1.450 |
Why?
|
| Meningeal Neoplasms | 6 | 2024 | 183 | 1.230 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 1084 | 0.720 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 160 | 0.720 |
Why?
|
| Hyperostosis Frontalis Interna | 1 | 2020 | 3 | 0.710 |
Why?
|
| Meningioma | 4 | 2024 | 120 | 0.670 |
Why?
|
| Somatosensory Cortex | 1 | 2019 | 49 | 0.630 |
Why?
|
| Research Design | 2 | 2023 | 679 | 0.620 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2015 | 207 | 0.600 |
Why?
|
| Therapies, Investigational | 1 | 2018 | 13 | 0.590 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2024 | 196 | 0.560 |
Why?
|
| Multiple Sclerosis | 2 | 2021 | 335 | 0.560 |
Why?
|
| Ganglioglioma | 1 | 2016 | 24 | 0.530 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2015 | 9 | 0.500 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 417 | 0.500 |
Why?
|
| Blindness | 1 | 2015 | 72 | 0.480 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2025 | 3549 | 0.470 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 489 | 0.470 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 105 | 0.440 |
Why?
|
| West Nile virus | 1 | 2015 | 117 | 0.430 |
Why?
|
| Mutation | 7 | 2025 | 5765 | 0.420 |
Why?
|
| West Nile Fever | 1 | 2015 | 139 | 0.420 |
Why?
|
| Humans | 46 | 2025 | 123254 | 0.410 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 240 | 0.410 |
Why?
|
| Epilepsy | 1 | 2020 | 858 | 0.410 |
Why?
|
| Neuroimaging | 1 | 2015 | 332 | 0.390 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2022 | 24 | 0.370 |
Why?
|
| Adult | 20 | 2025 | 29079 | 0.370 |
Why?
|
| Neoplasms | 4 | 2019 | 2757 | 0.350 |
Why?
|
| Body Height | 2 | 2021 | 211 | 0.330 |
Why?
|
| Aged | 15 | 2025 | 19173 | 0.330 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2022 | 244 | 0.330 |
Why?
|
| Middle Aged | 19 | 2025 | 26073 | 0.320 |
Why?
|
| Electroencephalography | 3 | 2020 | 857 | 0.300 |
Why?
|
| Retrospective Studies | 15 | 2024 | 16056 | 0.300 |
Why?
|
| Bevacizumab | 3 | 2017 | 63 | 0.290 |
Why?
|
| Female | 23 | 2025 | 65598 | 0.250 |
Why?
|
| Young Adult | 9 | 2021 | 8867 | 0.240 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1661 | 0.240 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1239 | 0.240 |
Why?
|
| Male | 20 | 2025 | 60310 | 0.230 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2023 | 18 | 0.210 |
Why?
|
| Olivary Nucleus | 1 | 2022 | 10 | 0.200 |
Why?
|
| Cerebellar Nuclei | 1 | 2022 | 15 | 0.200 |
Why?
|
| Headache | 2 | 2020 | 108 | 0.200 |
Why?
|
| Hypertrophy | 1 | 2022 | 101 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2019 | 67 | 0.190 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 109 | 0.190 |
Why?
|
| Cholangiocarcinoma | 1 | 2023 | 107 | 0.190 |
Why?
|
| Melanoma | 2 | 2022 | 824 | 0.190 |
Why?
|
| Radiotherapy | 2 | 2019 | 135 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2058 | 0.190 |
Why?
|
| Ependymoma | 1 | 2022 | 134 | 0.190 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2021 | 7 | 0.190 |
Why?
|
| JC Virus | 1 | 2021 | 28 | 0.180 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2021 | 32 | 0.180 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 35 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 6385 | 0.180 |
Why?
|
| Frontal Bone | 1 | 2020 | 16 | 0.180 |
Why?
|
| Survival Analysis | 3 | 2019 | 1473 | 0.170 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2019 | 19 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2019 | 4 | 0.160 |
Why?
|
| Socioeconomic Factors | 2 | 2022 | 865 | 0.160 |
Why?
|
| Oncogene Fusion | 1 | 2019 | 22 | 0.160 |
Why?
|
| Karnofsky Performance Status | 1 | 2019 | 14 | 0.160 |
Why?
|
| Optic Nerve Glioma | 1 | 2019 | 21 | 0.160 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2019 | 19 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 79 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 523 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 70 | 0.150 |
Why?
|
| Endpoint Determination | 1 | 2018 | 53 | 0.150 |
Why?
|
| Telomerase | 1 | 2019 | 161 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2019 | 137 | 0.150 |
Why?
|
| Erdheim-Chester Disease | 1 | 2017 | 23 | 0.150 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2017 | 18 | 0.140 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2017 | 16 | 0.140 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2017 | 17 | 0.140 |
Why?
|
| Third Ventricle | 1 | 2017 | 29 | 0.140 |
Why?
|
| Hemangioma, Cavernous | 1 | 2017 | 19 | 0.140 |
Why?
|
| Prognosis | 4 | 2019 | 4515 | 0.140 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 858 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 100 | 0.140 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 299 | 0.130 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 107 | 0.130 |
Why?
|
| Pandemics | 1 | 2024 | 1100 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 1006 | 0.130 |
Why?
|
| Spinal Cord | 1 | 2017 | 304 | 0.130 |
Why?
|
| Gliosarcoma | 1 | 2015 | 11 | 0.130 |
Why?
|
| Survival Rate | 2 | 2018 | 2001 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 1340 | 0.120 |
Why?
|
| Embolization, Therapeutic | 1 | 2017 | 226 | 0.120 |
Why?
|
| Incidence | 3 | 2020 | 3052 | 0.120 |
Why?
|
| Treatment Outcome | 7 | 2019 | 12165 | 0.120 |
Why?
|
| Hydrocephalus | 1 | 2017 | 242 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2844 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 372 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 940 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2021 | 6030 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2021 | 4705 | 0.110 |
Why?
|
| Wound Healing | 1 | 2015 | 451 | 0.100 |
Why?
|
| Israel | 2 | 2021 | 44 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 668 | 0.090 |
Why?
|
| Time Factors | 3 | 2018 | 6222 | 0.090 |
Why?
|
| Risk Factors | 4 | 2021 | 10036 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 1591 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 1112 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2021 | 99 | 0.080 |
Why?
|
| Adolescent | 4 | 2021 | 19131 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5049 | 0.060 |
Why?
|
| Age Factors | 2 | 2019 | 2806 | 0.050 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2022 | 34 | 0.050 |
Why?
|
| Dogs | 1 | 2024 | 764 | 0.050 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2022 | 110 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 164 | 0.050 |
Why?
|
| Dimethyl Fumarate | 1 | 2021 | 11 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2020 | 3336 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2022 | 185 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2022 | 189 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2024 | 530 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 222 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 100 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2020 | 69 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2024 | 547 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2019 | 107 | 0.040 |
Why?
|
| Intralaminar Thalamic Nuclei | 1 | 2017 | 6 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 34 | 0.040 |
Why?
|
| Dura Mater | 1 | 2017 | 26 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2022 | 816 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 669 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2019 | 210 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2017 | 168 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2018 | 355 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 645 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1265 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2018 | 179 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 535 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 604 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 419 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2015 | 45 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 113 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 104 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 1553 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1078 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 503 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 353 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2015 | 283 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 1397 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 713 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1314 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2030 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 716 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 2015 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 711 | 0.020 |
Why?
|
| Pregnancy | 1 | 2019 | 7128 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 2965 | 0.020 |
Why?
|
| Animals | 1 | 2024 | 33837 | 0.010 |
Why?
|